Skip to main navigation
Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® for Dry AMD
    • OPC1
    • Other Programs
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • News
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxy Information
      • 2018 AgeX and Form 10 Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu
  • Investors

    Lineage is a clinical-stage biotechnology company developing novel cell therapies

Investors

NYSE AMERICAN: LCTX

Minimum 15 minutes delayed. Source: LSEG

 
VIEW STOCK QUOTE
Press Releases
October 29, 2026
Lineage Provides Update on ReSonance® Program for Hearing Loss
September 08, 2026
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
August 06, 2026
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
VIEW PRESS RELEASES
Events & Presentations
Lineage Cell Therapeutics Corporate Overview (September 14, 2026) 4.7 MB
OpRegen® 3 Year Clinical Data Update (Retinal Innovation Summit 2026) 2.1 MB
Roche Pharma Day 2025 Presentation 8.1 MB
Second Quarter 2026 Financial Results Earnings Call
Aug 6, 2026 at 4:30 PM EDT
Click here for webcast
VIEW EVENTS & PRESENTATIONS
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   contact@lineagecell.com
  • Facebook
  • Twitter
  • RSS Feed
  • Email Alerts
Scroll to top